A detailed history of Ferguson Wellman Capital Management, Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ferguson Wellman Capital Management, Inc holds 4,994 shares of GILD stock, worth $456,201. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,994
Previous 4,831 3.37%
Holding current value
$456,201
Previous $404,000 3.47%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$66.59 - $83.99 $10,854 - $13,690
163 Added 3.37%
4,994 $418,000
Q3 2024

Oct 18, 2024

SELL
$66.59 - $83.99 $39,621 - $49,974
-595 Reduced 10.97%
4,831 $404,000
Q2 2024

Jul 16, 2024

SELL
$63.15 - $72.88 $5.25 Million - $6.06 Million
-83,184 Reduced 93.88%
5,426 $372,000
Q1 2024

Apr 09, 2024

SELL
$71.58 - $87.29 $1.28 Million - $1.56 Million
-17,839 Reduced 16.76%
88,610 $6.49 Million
Q4 2023

Jan 11, 2024

BUY
$73.27 - $83.09 $45,940 - $52,097
627 Added 0.59%
106,449 $8.62 Million
Q3 2023

Oct 12, 2023

SELL
$73.94 - $80.67 $12.3 Million - $13.4 Million
-166,358 Reduced 61.12%
105,822 $7.93 Million
Q2 2023

Jul 11, 2023

BUY
$76.01 - $86.7 $20.2 Million - $23.1 Million
265,943 Added 4263.96%
272,180 $21 Million
Q1 2023

Apr 20, 2023

SELL
$77.31 - $88.08 $6,184 - $7,046
-80 Reduced 1.27%
6,237 $517,000
Q4 2022

Jan 13, 2023

SELL
$62.32 - $89.47 $51,289 - $73,633
-823 Reduced 11.53%
6,317 $542,000
Q2 2022

Jul 14, 2022

SELL
$57.72 - $65.01 $17,316 - $19,503
-300 Reduced 4.03%
7,140 $441,000
Q1 2022

Apr 14, 2022

SELL
$57.92 - $72.58 $76,744 - $96,168
-1,325 Reduced 15.12%
7,440 $442,000
Q4 2021

Jan 10, 2022

BUY
$64.88 - $73.64 $14,468 - $16,421
223 Added 2.61%
8,765 $636,000
Q3 2021

Oct 22, 2021

SELL
$67.69 - $73.03 $2,233 - $2,409
-33 Reduced 0.38%
8,542 $597,000
Q2 2021

Jul 12, 2021

SELL
$63.47 - $69.35 $36,558 - $39,945
-576 Reduced 6.29%
8,575 $590,000
Q1 2021

Apr 26, 2021

SELL
$60.0 - $68.46 $160,500 - $183,130
-2,675 Reduced 22.62%
9,151 $591,000
Q4 2020

Feb 04, 2021

SELL
$56.65 - $64.55 $68,263 - $77,782
-1,205 Reduced 9.25%
11,826 $689,000
Q3 2020

Oct 13, 2020

SELL
$62.1 - $78.08 $271,563 - $341,443
-4,373 Reduced 25.13%
13,031 $823,000
Q2 2020

Aug 04, 2020

SELL
$72.34 - $84.0 $251,598 - $292,152
-3,478 Reduced 16.66%
17,404 $1.34 Million
Q1 2020

Apr 21, 2020

SELL
$62.63 - $80.22 $16 Million - $20.5 Million
-255,958 Reduced 92.46%
20,882 $1.56 Million
Q4 2019

Jan 24, 2020

SELL
$61.62 - $67.78 $1.59 Million - $1.75 Million
-25,775 Reduced 8.52%
276,840 $18 Million
Q3 2019

Oct 15, 2019

BUY
$62.51 - $69.0 $404,752 - $446,775
6,475 Added 2.19%
302,615 $19.2 Million
Q2 2019

Jul 16, 2019

BUY
$61.87 - $69.38 $1.1 Million - $1.23 Million
17,765 Added 6.38%
296,140 $20 Million
Q1 2019

Apr 11, 2019

SELL
$62.53 - $70.05 $5.18 Million - $5.8 Million
-82,838 Reduced 22.93%
278,375 $18.1 Million
Q4 2018

Jan 16, 2019

BUY
$60.54 - $79.0 $3.19 Million - $4.16 Million
52,660 Added 17.07%
361,213 $22.6 Million
Q3 2018

Oct 25, 2018

BUY
$71.28 - $78.92 $7.54 Million - $8.35 Million
105,818 Added 52.2%
308,553 $23.8 Million
Q2 2018

Aug 10, 2018

BUY
$64.88 - $75.68 $10.9 Million - $12.7 Million
167,280 Added 471.81%
202,735 $14.4 Million
Q1 2018

Apr 09, 2018

SELL
$72.84 - $88.8 $321,224 - $391,608
-4,410 Reduced 11.06%
35,455 $2.67 Million
Q4 2017

Jan 24, 2018

SELL
$71.15 - $83.52 $122,876 - $144,239
-1,727 Reduced 4.15%
39,865 $2.86 Million
Q3 2017

Oct 11, 2017

BUY
$72.11 - $85.47 $3 Million - $3.55 Million
41,592
41,592 $3.37 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Ferguson Wellman Capital Management, Inc Portfolio

Follow Ferguson Wellman Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ferguson Wellman Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ferguson Wellman Capital Management, Inc with notifications on news.